Online citations, reference lists, and bibliographies.
← Back to Search

Gemcitabine And Vinorelbine As Second-line Or Beyond Treatment In Patients With Malignant Pleural Mesothelioma Pretreated With Platinum Plus Pemetrexed Chemotherapy

G. Toyokawa, M. Takenoyama, F. Hirai, R. Toyozawa, Eiko Inamasu, M. Kojo, Y. Morodomi, Yoshimasa Shiraishi, T. Takenaka, M. Yamaguchi, M. Shimokawa, T. Seto, Y. Ichinose
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AbstractBackground Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that responds poorly to chemotherapy. Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM, the optimal second-line and beyond therapy has not yet been fully examined.MethodsBetween March 2008 and October 2011, 17 consecutive Japanese patients pretreated with at least one regimen of platinum plus pemetrexed chemotherapy received gemcitabine and vinorelbine. Responses, survival time, and toxicity were retrospectively evaluated.ResultsResponse [partial response (PR) + complete response (CR)] and disease control [stable disease (SD) + PR + CR] rates were 18 and 82 %, respectively. The median progression-free survival (PFS) after combination chemotherapy was 6.0 months, whereas the median overall survival (OS) was 11.2 months. Grade 3 or 4 neutropenia and anemia were observed in 41 and 29 % of patients, respectively, and one patient experienced febrile neutropenia. Grade 3 or 4 nonhematologic toxicities included constipation (6 %) and phlebitis (6 %).ConclusionCombination chemotherapy using gemcitabine with vinorelbine was shown to have moderate activity in Japanese MPM patients pretreated with platinum plus pemetrexed chemotherapy. A further multicenter phase II trial is warranted to confirm the efficacy and safety of this combination treatment.
This paper references
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
10.1056/NEJM196503182721104
RELATION BETWEEN EXPOSURE TO ASBESTOS AND MESOTHELIOMA.
I. Selikoff (1965)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1111/j.1349-7006.2011.02165.x
National survey of malignant mesothelioma and asbestos exposure in Japan
K. Gemba (2012)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/J.LUNGCAN.2005.03.029
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
E. Tan (2005)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1186/1745-6673-3-34
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)
10.1093/JJCO/HYI127
Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
R. Maruyama (2005)
10.1093/annonc/mds537
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Y. Tsutani (2013)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)



This paper is referenced by
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
10.4103/0366-6999.196585
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment
C. Ban (2017)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
10.21037/jtd.2017.10.19
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
10.3390/ijms20020429
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
A. Guazzelli (2019)
10.1055/s-0034-1365025
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
10.1016/j.ctrv.2015.10.006
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
G. Ceresoli (2015)
In vitro testing of drug sensitivity in tumor cells from effusion
Carl-Olof Hillerdal (2017)
Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014
(2019)
10.1634/theoncologist.2014-0122
Current issues in malignant pleural mesothelioma evaluation and management.
J. Ai (2014)
10.1007/s12032-014-0074-9
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
H. Mutlu (2014)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
10.1186/s12885-015-1881-x
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
C. Raynaud (2015)
10.1586/17476348.2015.1083426
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
10.18632/oncotarget.20889
Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
Carl-Olof Hillerdal (2017)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
10.1016/j.ejbas.2018.05.007
Malignant pleural mesothelioma: Presentation of a case report
Munir Ahmad (2018)
10.1007/s12032-014-0458-x
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma
V. A. B. Lima (2015)
Semantic Scholar Logo Some data provided by SemanticScholar